CO-DIAGNOSTICS, INC. Form 8-K (Nov. 11, 2021)

Summary

Current report on Form 8-K of Co-Diagnostics, Inc. reporting an event dated November 11, 2021. Under Items 2.02 and 7.01 the company states that it issued a press release announcing financial results for its quarter ended September 30, 2021, included as Exhibit 99.1. It states that it anticipates filing its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021 on or before November 15, 2021. The signature block carries /s/ Brian Brown, Chief Financial Officer (Principal Financial and Accounting Officer), dated November 11, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

FORM 8-K

CURRENT
REPORT

Pursuant
to Section 13 or 15(d) of the

Securities
Exchange Act of 1934

Date
of report (Date of earliest event reported): November 11, 2021

CO-DIAGNOSTICS,
INC.

(Exact
name of small business issuer as specified in its charter)

Utah | 1-38148 | 46-2609363
(State
 or other jurisdiction of | (Commission | (IRS
 Employer
incorporation
 or organization) | File
 Number) | Identification
 Number)

2401
S. Foothill Drive , Suite D , Salt Lake City , Utah 84109

(Address
of principal executive offices)

(801) 438-1036

(Issuer’s
telephone number)

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

☐ | Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities
registered pursuant to Section 12(b) of the Act:

Title
 of each class | Trading
 Symbol(s) | Name
 of each exchange on which registered
Common
 Stock, par value $0.001 per share | CODX | The Nasdaq Capital Market

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company ☒

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item
2.02. Results of Operations and Financial Condition.

Item
7.01. Regulation FD. Disclosure.

On
November 11, 2021, Co-Diagnostics, Inc. (the “ Company ”) issued a press release announcing financial results for its
quarter ended September 30, 2021. A copy of the press release is included as Exhibit 99.1 and incorporated herein by reference. The Company
anticipates filing its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021 with the U.S. Securities and Exchange
Commission on or before November 15, 2021.

The
disclosures under Item 2.02 and Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.
The information provided herein shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933,
as amended, except as expressly set forth by specific reference in such filing.

Item
9.01 Financial Statements and Exhibits.

(d)
Exhibits

Exhibit
 No.: | Description:
99.1 | Press Released, dated November 11, 2021
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.

CO-DIAGNOSTICS,
 INC.
Date: November 11, 2021 | By: | /s/
 Brian Brown
Name: | Brian
 Brown
Title: | Chief
 Financial Officer (Principal
 Financial and Accounting Officer)

File and source

File

SEC_CODX_8-K_filed2021-11-12_0001493152-21-027932.htm

Size

33,894 bytes

SHA-256

84e6fd78780c8180a592b0e6f361dc4653618e76260793d123a3e8334643f8dd

Our copy

SEC_CODX_8-K_filed2021-11-12_0001493152-21-027932.htm

Original

www.sec.gov